ArticleMolecular biotechnology2026
Development and Validation of Real-Time Allele-Specific PCR-Based Genotyping of the rs1042713 Variant in the ADRB2 Gene and Its Correlation with Salbutamol Response.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the Association Between theCurrent issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a prevalent chronic respiratory disease influenced by genetic and environmental factors. The beta-2 adrenergic receptor (ADRB2) gene, located on chromosome 5q31-q32, plays a crucial role in bronchodilation by regulating airway smooth muscle relaxation through cyclic adenosine monophosphate (cAMP)-mediated signaling. Genetic variations in ADRB2, particularly + 46A > G (Arg16Gly, rs1042713) and + 79C > G (Gln27Glu, rs1042714), have been associated with altered receptor function, potentially impacting bronchodilator response to β2adrenergic receptor agonists such as salbutamol. Studies suggest that individuals with specific ADRB2 polymorphisms may exhibit variable drug efficacy, influencing asthma treatment outcomes. This study aims to investigate the association between ADRB2 polymorphism (Arg16Gly, rs1042713) and bronchodilator response, assessing their role in inter-individual variability in salbutamol efficacy. Allele-specific PCR (AS-PCR) employed to genotype these polymorphisms help in distinguishing homozygous and heterozygous variants. The findings could contribute to personalized asthma management, optimizing pharmacogenetic-based treatment strategies for improved therapeutic outcomes in a cost effective setting. Understanding the genetic basis of β2-AR variability may facilitate tailored asthma interventions, reducing adverse drug reactions and enhancing patient care.
Indexed as
Identifiers
40730704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.